TROP2 CAR IL-15-transduced cord blood-derived NK cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for TROP2 CAR IL-15-transduced cord blood-derived NK cells, covering 2026-02-19 to 2026-02-19. Get the full timeline:
Most recent: Clinical Trial Update: Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer [Phase 1, Phase 2]